Filing Flows › Heron Therapeutics (HRTX) › Q3 2026 › vs Q2 2026
Heron Therapeutics (HRTX) Q3 2026 vs Q2 2026 (quarter over quarter)
Heron Therapeutics's revenue fell $2.4M (-6%) from $37.7M in Q2 2026 to $35.2M in Q3 2026. The biggest changes: CINVANTI −$1.8M (-8%); ZYNRELEF −$458K (-4%); SUSTOL −$388K (-72%).
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| CINVANTI | $20.0M | $21.8M | −$1.8M | -8% |
| ZYNRELEF | $10.6M | $11.1M | −$458K | -4% |
| Aponvie | $4.5M | $4.3M | $253K | +6% |
| SUSTOL | $152K | $540K | −$388K | -72% |
| Revenue | $35.2M | $37.7M | −$2.4M | -6% |
| Net loss | $5.0M | $5.5M | −$483K | -9% |
| Costs & expenses | $40.3M | $43.2M | −$2.9M | -7% |
| Operating costs | $36.9M | $39.7M | −$2.8M | -7% |
| Interest & other, net | $3.3M | $3.4M | −$108K | -3% |
| Cost of revenue | $9.0M | $11.6M | −$2.6M | -23% |
| Research & development | $3.1M | $2.7M | $397K | +15% |
| Sales & marketing | $12.5M | $14.2M | −$1.6M | -12% |
| General & admin | $12.3M | $11.3M | $1.1M | +9% |
| Operating cash sources | $5.0M | $5.5M | −$483K | -9% |
| Depreciation & amortization | $391K | $452K | −$61K | -13% |
| Share-based compensation | $3.1M | $3.2M | −$95K | -3% |
| Working capital & other | $738K | −$354K | $1.1M | — |
| Cash used in operations | $794K | $2.2M | −$1.4M | -64% |
| Net loss absorbed | $5.0M | $5.5M | −$483K | -9% |
Questions
How much did Heron Therapeutics's revenue grow quarter over quarter in Q3 2026?
Heron Therapeutics's revenue fell $2.4M (-6%) from $37.7M in Q2 2026 to $35.2M in Q3 2026.
What drove Heron Therapeutics's revenue change in Q3 2026?
CINVANTI −$1.8M (-8%); ZYNRELEF −$458K (-4%); SUSTOL −$388K (-72%).